文献速递膀胱癌与上尿路尿路上皮癌

NAI联合BCG在BCG无应答NMIBC伴CIS±乳头状病变中持久缓解并避免膀胱切除

Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease.
PubMed 文献 · J Urol · 2026-07-06

QUILT-3.032研究长期随访显示,BCG无应答的非肌层浸润性膀胱癌(NMIBC)伴原位癌(CIS)±乳头状病变患者接受NAI(400 mcg)联合BCG(50 mg)膀胱灌注,完全缓解率71%(95%CI 61.1-79.6),中位缓解持续时间26.6个月,36个月无膀胱切除率84.2%,疾病特异性生存率98.2%。

要点

  • NAI联合BCG在BCG无应答NMIBC伴CIS±Ta/T1中完全缓解率达71%。
  • 36个月无膀胱切除率84.2%,疾病特异性生存率98.2%。
  • 治疗相关不良事件以1-2级为主(59%),无4-5级事件。

核心结论

  • NAI联合BCG对BCG无应答NMIBC伴CIS±Ta/T1安全有效,可持久缓解并避免膀胱切除。

研究设计与样本

  • QUILT-3.032研究长期随访,参与者接受NAI 400 mcg联合BCG 50 mg膀胱灌注每周6周,3个月未达完全缓解可再诱导,样本量n=100。

主要发现

  • 完全缓解率71%(95%CI 61.1-79.6),中位缓解持续时间26.6个月(范围0.03-53.62)。
  • 71例缓解者24和36个月Kaplan-Meier估计无膀胱切除率分别为90.3%(95%CI 79.7-95.6)和84.2%(95%CI 69.6-92.1)。
  • 疾病特异性生存率12个月100%(95%CI 100.0-100.0),36个月98.2%(95%CI 88.2-99.8)。
  • 治疗相关不良事件1-2级占59%,3级占4%,无4级或5级事件。

临床怎么用

  • 对于BCG无应答NMIBC伴CIS±Ta/T1,可考虑NAI联合BCG膀胱灌注以争取持久缓解和保膀胱。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We report long-term follow-up on participants in the QUILT-3.032 study in bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle-invasive bladder cancer (NMIBC) carcinoma in situ (CIS) ± papillary disease using nogapendekin alfa inbakicept-pmln (NAI, N-803) approved by the Food and Drug Administration (Anktiva) in combination with BCG. MATERIALS AND METHODS: Participants received 400 mcg NAI in combination with 50 mg BCG through intravesical instillation weekly for 6 weeks, with optional reinduction if complete response (CR) was not achieved at month 3. Primary end point was CR rate at any time; secondary end points were duration of CR, progression-free survival, overall survival, disease-specific survival (DSS), and time to cystectomy. RESULTS: The CR rate (n = 100) was 71% (95% CI 61.1-79.6) with a median duration of CR of 26.6 months (range 0.03-53.62). The Kaplan-Meier estimated cystectomy-free rate in the 71 responders at 24 and 36 months was 90.3% (95% CI 79.7-95.6) and 84.2% (95% CI 69.6-92.1), respectively. DSS was 100% (95% CI 100.0-100.0) at 12 months and 98.2% (95% CI 88.2-99.8) at 36 months. Treatment-related adverse events were largely grade 1 to 2 (59%), with 4% grade 3 and no grade 4 or 5 treatment-related adverse events observed with this biological combination. CONCLUSIONS: The CR rate and durability of responses that surpass 53 months reveal the efficacy of NAI in combination with BCG for treating BCG-unresponsive NMIBC with CIS ± Ta/T1 disease. The high cystectomy-free rate of 84% and DSS of 98% at 36 months suggest that NAI plus BCG is a safe and efficacious option for NMIBC with CIS ± Ta/T1 disease.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Chang SS, Chamie K, Seabury CA, et al. Durable Responses and Cystectomy Avoidance With Interleukin-15 Receptor Agonist NAI Plus Bacillus Calmette-Guérin in Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer With Carcinoma In Situ ± Papillary Disease. J Urol. 2026. PMID: 42406609. doi:10.1097/JU.0000000000005198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。